Related Experiment Video
Updated: Apr 10, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis
Valeria Sainz-Prestel1, Jesus Hernandez-Perez1, Jorge Rojas-Rivera1
1Nephrology , IIS-Fundación Jimenez Diaz/UAM/IRSIN , Madrid , Spain ; REDINREN.
Abstract:
Rituximab (RTX) is a chimeric monoclonal antibody against CD20+ B cells increasingly used to treat kidney disorders. RTX-induced pulmonary disease has been reported in patients treated for haematological disorders, and a few cases have been observed in patients with underlying rheumatological conditions. We report a case of non-infectious interstitial pneumonitis associated with RTX use in a 49-year-old patient with primary (fibrillary) glomerulonephritis. As typically observed, discontinuation of the drug and prompt initiation of glucocorticoids led to resolution of pulmonary manifestations. However, fatalities have been reported and nephrologists treating glomerulonephritis patients with RTX should be aware of the existence of this potentially lethal complication.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome I : Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

